Abstract

Real-world data are limited on tenofovir alafenamide (TAF). We aimed to study TAF real-world outcomes with other first-line regimens for chronic hepatitis B (CHB). We enrolled patients with CHB from 10 centers retrospectively and followed them for 36months prospectively. We analyzed switching patterns of antiviral therapy and treatment outcomes of TAF, tenofovir disoproxil fumarate (TDF), and entecavir therapy. For efficacy and safety, we analyzed a subset of patients with complete data at 24months after switching to TAF or remaining on TDF or entecavir. Among 1037 enrollees, 889 patients were analyzed. The mean age was 52%, and 72% were hepatitis B e antigen-negative. After enrollment, shifts in therapies were mostly in reduced use of TDF from 63% to 30% due to switching to TAF. Clinical parameters were compared at enrollment or initiation to measures at 24months for patients remaining on TAF (187), TDF (229), or entecavir (181). At 24months, a significantly higher portion of patients on TAF achieved hepatitis B virus (HBV) DNA =20IU/ml (93% vs. 86%; p=0.012) and normalized alanine aminotransferase (ALT) (66% vs. 56%; p=0.031) with stable estimated glomerular filtration rates (eGFRs). However, a higher percentage of the patient with eGFR <60ml/mi/1.7m2 was observed in the TDF-treated group (9% vs. 4%; p=0.010). In patients who remained on entecavir or TDF for 24months, ALT and HBV-DNA results did not differ significantly from baseline. Treatment of CHB in the United States has significantly shifted from TDF to TAF. Our data suggest that switching from TDF or entecavir to TAF may result in increased frequency of ALT normalization and potential clearance of viremia at the 24-month time point.

View details for DOI 10.1002/hep4.1964

View details for PubMedID 35445803